These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 17934393)
1. Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Watson KE Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393 [TBL] [Abstract][Full Text] [Related]
2. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Hollander P Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341 [TBL] [Abstract][Full Text] [Related]
3. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
4. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J; JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899 [TBL] [Abstract][Full Text] [Related]
5. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O; Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461 [TBL] [Abstract][Full Text] [Related]
6. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Després JP; Ross R; Boka G; Alméras N; Lemieux I; Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166 [TBL] [Abstract][Full Text] [Related]
8. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Scheen AJ J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513 [TBL] [Abstract][Full Text] [Related]
9. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna. Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035 [No Abstract] [Full Text] [Related]
10. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Tonstad S Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916 [TBL] [Abstract][Full Text] [Related]
11. The progression of cardiovascular risk to cardiovascular disease. Rosin BL Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392 [TBL] [Abstract][Full Text] [Related]
12. Metabolic risk factors, drugs, and obesity. Padwal R; Majumdar S N Engl J Med; 2006 Mar; 354(9):974-5; author reply. PubMed ID: 16510755 [No Abstract] [Full Text] [Related]
13. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Gelfand EV; Cannon CP J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306 [TBL] [Abstract][Full Text] [Related]
14. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Cox SL Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease under the influence of excess visceral fat. Després JP Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491 [TBL] [Abstract][Full Text] [Related]
17. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428 [TBL] [Abstract][Full Text] [Related]
18. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Scheen AJ; Van Gaal LF Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296 [TBL] [Abstract][Full Text] [Related]
19. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Wierzbicki AS Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677 [TBL] [Abstract][Full Text] [Related]